{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05744466",
            "orgStudyIdInfo": {
                "id": "IM011-1105"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis",
            "officialTitle": "A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region",
            "acronym": "RePhlect",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "a-real-world-observational-study-to-compare-effectiveness-of-deucravacitinib-vs-apremilast-in-adults-with-plaque-psoriasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-30",
            "studyFirstSubmitQcDate": "2023-02-15",
            "studyFirstPostDateStruct": {
                "date": "2023-02-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis"
            ],
            "keywords": [
                "Real-world",
                "Deucravacitinib",
                "Observational"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 1500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "description": "Participants that have initiated deucravacitinib",
                    "interventionNames": [
                        "Drug: Deucravacitinib"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "description": "Participants that have initiated apremilast",
                    "interventionNames": [
                        "Drug: Apremilast"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Deucravacitinib",
                    "description": "As prescribed by treating clinician",
                    "armGroupLabels": [
                        "Cohort 1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Apremilast",
                    "description": "As prescribed by treating clinician",
                    "armGroupLabels": [
                        "Cohort 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in body surface area (BSA)",
                    "timeFrame": "At baseline and every 6 months up to 60 months or treatment discontinuation"
                },
                {
                    "measure": "Investigator global assessment (IGA) response 0/1",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Dermatology life quality index (DLQI) response 0/1",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Time from date of treatment initiation to date of discontinuation",
                    "timeFrame": "Up to 60 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "75 percent improvement in Psoriasis area and severity index (PASI) score",
                    "timeFrame": "At baseline and every 6 months up to 60 months or treatment discontinuation"
                },
                {
                    "measure": "PASI score response \u2264 3",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "PASI score response \u2264 5",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "PASI score change from baseline",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "National psoriasis foundation (NPF) acceptable body surface area (BSA) response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "NPF target BSA response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "BSA \u22643%",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Change in investigator global assessment (IGA) score",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Change in dermatology life quality index (DLQI) response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Change in DLQI response \u22645",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Change in visual analog scale (VAS): Itch response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Change in VAS: Skin Pain response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Change in VAS: Fatigue Response",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                },
                {
                    "measure": "Merit-based Incentive Payment System (MIPS) Clinical Response to Oral Systemic or Biologic Medications",
                    "timeFrame": "At baseline to follow-up, up to 60 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have been diagnosed with plaque psoriasis by a dermatologist\n* Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)\n* Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes\n\nExclusion Criteria:\n\n* Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)\n* Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Adults diagnosed with moderate-to-severe plaque psoriasis who initiate deucravacitinib or apremilast within the CorEvitas Psoriasis Registry will be enrolled. Participants will be followed every 6 months from initiation up to 5 years or discontinuation, whichever occurs first. This is a real-world study and hence the follow-up are done based on the clinical practice done by dermatologists.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain the NCT# and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Local Institution",
                    "status": "RECRUITING",
                    "city": "Waltham",
                    "state": "Massachusetts",
                    "zip": "02451",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.37649,
                        "lon": -71.23561
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000505730",
                    "term": "Apremilast"
                },
                {
                    "id": "C000628674",
                    "term": "Deucravacitinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000894",
                    "term": "Anti-Inflammatory Agents, Non-Steroidal"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000058988",
                    "term": "Phosphodiesterase 4 Inhibitors"
                },
                {
                    "id": "D000010726",
                    "term": "Phosphodiesterase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M346703",
                    "name": "Deucravacitinib",
                    "asFound": "Flavonoids",
                    "relevance": "HIGH"
                },
                {
                    "id": "M341074",
                    "name": "Apremilast",
                    "asFound": "Strengthening exercises",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4218",
                    "name": "Anti-Inflammatory Agents, Non-Steroidal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29334",
                    "name": "Phosphodiesterase 4 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M13629",
                    "name": "Phosphodiesterase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}